Sharon S. Allen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Sharon S. Allen has a total of 327 co-authors. Here are the top co-authors by number of shared publications:
- Alicia Marie Allen
National Center for Opioid and Addiction Research, Arkansas Children's Research Institute, 13 Children's Way, Slot 842, Little Rock, AR 72202, United States
19 shared publications - Mustafa Al'Absi
Department of Family Medicine and Biobehavioral Health, University of Minnesota Medical School, Duluth, USA
15 shared publications Dorothy Hatsukami
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States of America
14 shared publications- Dorothy K. Hatsukami
Masonic Cancer Center University of Minnesota Minneapolis MN USA
12 shared publications Dorothy K. Hatsukami
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States of America
9 shared publicationsJoni Jensen
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States of America
7 shared publications
Latest Publications
- 31 December 2024
- Published by Springer Nature in Journal of Behavioral Medicine
- Vol. 48 (2) , 341-348
A remote examination of acute stress responses: examining the influence of psychological resilience
Background A few studies have examined psychological resilience as a predictor of physiological responses to acute stress; however, no studies have directly examined psychological resilience as a moderator of subjective responses to acute stress. Methods Adults were recruited to participate in an acute stress response study that was conducted remotely. Demographics, psychological resilience, nicotine use and desire to quit, and information related to cannabis use were measured during a medical screening session. Positive, stressed, and anxious moods were measured during baseline rest prior to acute stress, after performing acute stress tasks, and after 30- and 55-minutes of post-stress recovery during an acute stress session. Results Acute stress was successfully induced during the remote audio-video stress session. There were significant increases in stressed and anxious moods and significant decreases in positive mood immediately after the acute stress tasks, followed by a return to baseline levels of these moods. Moreover, psychological resilience was inversely related to stressed and anxious moods reported at baseline and immediately after acute stress. In addition, psychological resilience was positively related to positive mood. Conclusion The results are consistent with previous research linking psychological resilience to general reports of positive and negative affect. Further, the results demonstrate, for the first time, that psychological resilience may be a significant predictor of negative mood immediately after acute stress.
- 31 December 2024
- Published by Springer Nature in Journal of Behavioral Medicine
- Vol. 48 (2) , 341-348
A remote examination of acute stress responses: examining the influence of psychological resilience
Background A few studies have examined psychological resilience as a predictor of physiological responses to acute stress; however, no studies have directly examined psychological resilience as a moderator of subjective responses to acute stress. Methods Adults were recruited to participate in an acute stress response study that was conducted remotely. Demographics, psychological resilience, nicotine use and desire to quit, and information related to cannabis use were measured during a medical screening session. Positive, stressed, and anxious moods were measured during baseline rest prior to acute stress, after performing acute stress tasks, and after 30- and 55-minutes of post-stress recovery during an acute stress session. Results Acute stress was successfully induced during the remote audio-video stress session. There were significant increases in stressed and anxious moods and significant decreases in positive mood immediately after the acute stress tasks, followed by a return to baseline levels of these moods. Moreover, psychological resilience was inversely related to stressed and anxious moods reported at baseline and immediately after acute stress. In addition, psychological resilience was positively related to positive mood. Conclusion The results are consistent with previous research linking psychological resilience to general reports of positive and negative affect. Further, the results demonstrate, for the first time, that psychological resilience may be a significant predictor of negative mood immediately after acute stress.
- Open Access
- 6 November 2024
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 42, 101389
A protocol for modifying progesterone to increase postpartum cigarette smoking abstinence and reduce secondhand smoke exposure in infants
- 6 November 2024
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 42, 101389
Open AccessA protocol for modifying progesterone to increase postpartum cigarette smoking abstinence and reduce secondhand smoke exposure in infants
- Open Access
- 16 December 2022
- Published by Cambridge University Press (CUP) in Journal of Smoking Cessation
- Vol. 2022, 1925071
Knowledge, Attitudes, and Beliefs about Relapse Prevention Research Involving Bupropion among Current and Former Pregnant Individuals Who Smoke
Introduction. While many individuals quit smoking during pregnancy, most relapse within one year postpartum. Research into methods to decrease smoking relapse postpartum has been hampered by difficulties with recruitment. Method. We conducted individual interviews with pregnant women (N = 22) who were interested in quitting smoking while pregnant about their attitudes regarding smoking and quitting during pregnancy, clinical trial participation, and smoking cessation medication use. Results. Participants were aware of the risks of smoking while pregnant. Many wanted to quit smoking before delivery. Few used empirically supported treatments to quit. While research was viewed positively, interest in taking on new commitments postpartum and taking a medication to prevent relapse was low. Medication concerns were evident among most participants, especially among those planning to breastfeed. Further, several women noted medication was unnecessary, as they did not believe they would relapse postpartum. Financial incentives, childcare, and fewer and/or remote visits were identified as facilitators to participating in research. However, these factors did not outweigh women’s concerns about medication use and time commitments. Conclusions. Women are aware that quitting smoking during pregnancy and remaining smoke-free postpartum are important. However, beliefs that personal relapse risk is low and that medications are dangerous reduced enthusiasm for taking medication for postpartum relapse prevention. Future medication trials should educate women about the high likelihood of relapse, prepare to answer detailed questions about risks of cessation medications, and connect with participants’ clinicians. For new mothers, studies conducted remotely with few scheduled appointments would reduce barriers to participation.
- 16 December 2022
- Published by Cambridge University Press (CUP) in Journal of Smoking Cessation
- Vol. 2022, 1925071
Open AccessKnowledge, Attitudes, and Beliefs about Relapse Prevention Research Involving Bupropion among Current and Former Pregnant Individuals Who Smoke
Introduction. While many individuals quit smoking during pregnancy, most relapse within one year postpartum. Research into methods to decrease smoking relapse postpartum has been hampered by difficulties with recruitment. Method. We conducted individual interviews with pregnant women (N = 22) who were interested in quitting smoking while pregnant about their attitudes regarding smoking and quitting during pregnancy, clinical trial participation, and smoking cessation medication use. Results. Participants were aware of the risks of smoking while pregnant. Many wanted to quit smoking before delivery. Few used empirically supported treatments to quit. While research was viewed positively, interest in taking on new commitments postpartum and taking a medication to prevent relapse was low. Medication concerns were evident among most participants, especially among those planning to breastfeed. Further, several women noted medication was unnecessary, as they did not believe they would relapse postpartum. Financial incentives, childcare, and fewer and/or remote visits were identified as facilitators to participating in research. However, these factors did not outweigh women’s concerns about medication use and time commitments. Conclusions. Women are aware that quitting smoking during pregnancy and remaining smoke-free postpartum are important. However, beliefs that personal relapse risk is low and that medications are dangerous reduced enthusiasm for taking medication for postpartum relapse prevention. Future medication trials should educate women about the high likelihood of relapse, prepare to answer detailed questions about risks of cessation medications, and connect with participants’ clinicians. For new mothers, studies conducted remotely with few scheduled appointments would reduce barriers to participation.
- 18 June 2021
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 225, 108819
Tobacco withdrawal increases junk food intake: The role of the endogenous opioid system
- 18 June 2021
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 225, 108819
Tobacco withdrawal increases junk food intake: The role of the endogenous opioid system
- 9 March 2021
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 105, 106352
Bupropion for postpartum smoking relapse: A remote protocol for a two-arm, double-blind, placebo-controlled randomized clinical trial
- 9 March 2021
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 105, 106352
Bupropion for postpartum smoking relapse: A remote protocol for a two-arm, double-blind, placebo-controlled randomized clinical trial
- 22 July 2020
- Published by Elsevier in Addictive Behaviors
- Vol. 112, 106570
Effect of exogenous progesterone administration on smoking topography
- 22 July 2020
- Published by Elsevier in Addictive Behaviors
- Vol. 112, 106570
Effect of exogenous progesterone administration on smoking topography
- 1 June 2020
- Published by American Psychological Association (APA) in Experimental and Clinical Psychopharmacology
- Vol. 28 (3) , 306-316
Response to nicotine following overnight smoking abstinence during short-term progesterone treatment in women.
Preclinical and clinical literature suggest that sex hormones impact tobacco use behaviors in women. The goal of this double-blind crossover laboratory study was to examine the effect of oral exogenous progesterone (200 mg twice per day) versus placebo on nicotine response using measures of motor speed and cognitive function in women following overnight smoking abstinence. We hypothesized that increased progesterone would blunt the nicotine response whereby producing less change in motor speed and cognition in response to nicotine exposure. Female smokers, age 18-35, were randomized to participate in two 9-day crossover testing weeks. Participants completed a lab session following overnight abstinence where they were administered nicotine nasal spray and asked to complete measures of immediate memory (IMT), delayed memory (DMT), word recall (WR), and finger tapping speed (FT). After the first 9-day testing week, participants resumed smoking and returned the following month to complete the identical lab session in the crossover condition. Forty-seven women were included in this analysis (n = 47). We found no differences in the magnitude of response for IMT, DMT, and WR between conditions. For FT, women had a blunted response to nicotine during the placebo condition. When examining the association between hormone levels and relative performance, we found increases in DMT, WR, and FT but decreases in IMT during the progesterone condition. We observed differences between progesterone versus placebo in relative change in some measures of nicotine response following overnight abstinence. Future studies are needed to further characterize this response. (PsycInfo Database Record (c) 2020 APA, all rights reserved).
- 1 June 2020
- Published by American Psychological Association (APA) in Experimental and Clinical Psychopharmacology
- Vol. 28 (3) , 306-316
Response to nicotine following overnight smoking abstinence during short-term progesterone treatment in women.
Preclinical and clinical literature suggest that sex hormones impact tobacco use behaviors in women. The goal of this double-blind crossover laboratory study was to examine the effect of oral exogenous progesterone (200 mg twice per day) versus placebo on nicotine response using measures of motor speed and cognitive function in women following overnight smoking abstinence. We hypothesized that increased progesterone would blunt the nicotine response whereby producing less change in motor speed and cognition in response to nicotine exposure. Female smokers, age 18-35, were randomized to participate in two 9-day crossover testing weeks. Participants completed a lab session following overnight abstinence where they were administered nicotine nasal spray and asked to complete measures of immediate memory (IMT), delayed memory (DMT), word recall (WR), and finger tapping speed (FT). After the first 9-day testing week, participants resumed smoking and returned the following month to complete the identical lab session in the crossover condition. Forty-seven women were included in this analysis (n = 47). We found no differences in the magnitude of response for IMT, DMT, and WR between conditions. For FT, women had a blunted response to nicotine during the placebo condition. When examining the association between hormone levels and relative performance, we found increases in DMT, WR, and FT but decreases in IMT during the progesterone condition. We observed differences between progesterone versus placebo in relative change in some measures of nicotine response following overnight abstinence. Future studies are needed to further characterize this response. (PsycInfo Database Record (c) 2020 APA, all rights reserved).
Cannabis use and stressful life events during the perinatal period: cross‐sectional results from Pregnancy Risk Assessment Monitoring System (PRAMS) data, 2016
Aims: We aimed to determine the association between stressful life events (SLEs) in the year prior to childbirth with (1) pre‐pregnancy cannabis use, (2) cessation of cannabis use during pregnancy and (3) postpartum relapse to cannabis use.Design: We used data from the Pregnancy Risk Assessment Monitoring System (PRAMS) 2016, a cross‐sectional, population‐based surveillance system.Setting: Mailed and telephone surveys conducted in five states—Alaska, Colorado, Maine, Michigan and Washington—in the United States.Participants: Women (n = 6061) who delivered a live infant within the last 6 months and had data on cannabis use.Measurements: Self‐reported data included SLEs (yes/no response for 14 individual events in the 12 months prior to childbirth) and cannabis use [yes/no prior to pregnancy, during pregnancy, and at the time of the survey (approximately 2–6 months postpartum)]. The associations between SLEs and cannabis use (primary outcomes) were examined in logistic regression models adjusted for maternal demographics (e.g. age, race, education), geography (i.e. state of residence) and cigarette smoking.Findings: Pre‐pregnancy, 16.4% (997/6061) of respondents endorsed using cannabis, with 36.4% (363/997) continuing cannabis use during pregnancy. Among the 63.6% (634/997) who did not report use during pregnancy, 23.2% (147/634) relapsed to cannabis use during the postpartum. Nine of the 14 possible SLEs were associated with increased odds of pre‐pregnancy cannabis use [e.g. husband/partner or mother went to jail, adjusted odds ratio (aOR) = 2.16, 95% confidence interval (CI) = 1.30–3.62] and four were associated with increased odds of continued cannabis use during pregnancy (e.g. husband/partner lost job, aOR = 2.19, 95% CI = 1.21–3.96). The odds of postpartum relapse to cannabis were significantly associated with two SLEs (husband/partner said they did not want pregnancy, aOR = 2.86, CI = 1.10–7.72; husband/partner or mother went to jail, aOR = 0.37, 95% CI = 0.13–1.00).Conclusions: Stressful life events during the year prior to childbirth appear to be linked to greater odds of women's cannabis use during the perinatal period, especially during pre‐pregnancy.
Cannabis use and stressful life events during the perinatal period: cross‐sectional results from Pregnancy Risk Assessment Monitoring System (PRAMS) data, 2016
Aims: We aimed to determine the association between stressful life events (SLEs) in the year prior to childbirth with (1) pre‐pregnancy cannabis use, (2) cessation of cannabis use during pregnancy and (3) postpartum relapse to cannabis use.Design: We used data from the Pregnancy Risk Assessment Monitoring System (PRAMS) 2016, a cross‐sectional, population‐based surveillance system.Setting: Mailed and telephone surveys conducted in five states—Alaska, Colorado, Maine, Michigan and Washington—in the United States.Participants: Women (n = 6061) who delivered a live infant within the last 6 months and had data on cannabis use.Measurements: Self‐reported data included SLEs (yes/no response for 14 individual events in the 12 months prior to childbirth) and cannabis use [yes/no prior to pregnancy, during pregnancy, and at the time of the survey (approximately 2–6 months postpartum)]. The associations between SLEs and cannabis use (primary outcomes) were examined in logistic regression models adjusted for maternal demographics (e.g. age, race, education), geography (i.e. state of residence) and cigarette smoking.Findings: Pre‐pregnancy, 16.4% (997/6061) of respondents endorsed using cannabis, with 36.4% (363/997) continuing cannabis use during pregnancy. Among the 63.6% (634/997) who did not report use during pregnancy, 23.2% (147/634) relapsed to cannabis use during the postpartum. Nine of the 14 possible SLEs were associated with increased odds of pre‐pregnancy cannabis use [e.g. husband/partner or mother went to jail, adjusted odds ratio (aOR) = 2.16, 95% confidence interval (CI) = 1.30–3.62] and four were associated with increased odds of continued cannabis use during pregnancy (e.g. husband/partner lost job, aOR = 2.19, 95% CI = 1.21–3.96). The odds of postpartum relapse to cannabis were significantly associated with two SLEs (husband/partner said they did not want pregnancy, aOR = 2.86, CI = 1.10–7.72; husband/partner or mother went to jail, aOR = 0.37, 95% CI = 0.13–1.00).Conclusions: Stressful life events during the year prior to childbirth appear to be linked to greater odds of women's cannabis use during the perinatal period, especially during pre‐pregnancy.
- 1 March 2020
- Published by Elsevier in Addictive Behaviors
- Vol. 102, 106148
Effect of exogenous progesterone administration on cigarette smoking-related symptomology in oral contraceptive users who smoke
- 1 March 2020
- Published by Elsevier in Addictive Behaviors
- Vol. 102, 106148
Effect of exogenous progesterone administration on cigarette smoking-related symptomology in oral contraceptive users who smoke